Market Place
Sourcing Support
Arvinas-Pfizer Partner Cancer Drug Trial Shows 63% Benefit
11 Dec 2024 //
PRESS RELEASE
Arvinas`s Vepdegestrant Posters at 2024 San Antonio Symposium
25 Nov 2024 //
GLOBENEWSWIRE
Arvinas & Pfizer announce updated clinical data from Ph1b Trial of Vepdegestrant
18 May 2024 //
INDINPHARMAPOST
Arvinas, Pfizer Update Vepdegestrant + Palbociclib Phase 1b Data
16 May 2024 //
GLOBENEWSWIRE
Arvinas Vepdegestrant Posters At ESMO Breast Cancer Congress 2024
09 May 2024 //
GLOBENEWSWIRE
Carrick Announces First Patient Dosed in Phase 1b/2 Trial of Samuraciclib
14 Feb 2024 //
GLOBENEWSWIRE
Arvinas and Pfizers Vepdegestrant (ARV-471) Receives FDA Fast Track Designation
06 Feb 2024 //
GLOBENEWSWIRE
Arvinas and Pfizer Announce Updated Vepdegestrant (ARV-471) Data
28 Nov 2023 //
GLOBENEWSWIRE
Arvinas & Pfizer Announce Upcoming Vepdegestrant (ARV-471) Poster Presentation
15 Oct 2023 //
GLOBENEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.